(Total Views: 354)
Posted On: 06/22/2022 7:29:18 AM
Post# of 117
ACADIA PHARMACEUTICALS: WHAT’S NEXT AFTER THE NEGATIVE FDA ADCOM?
$ACAD
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company developing small molecule drugs for treating central nervous system disorders, faced a setback at the FDA's Psychopharmacologic Drugs Advisory Committee (PDAC) meeting for pimavanserin, a drug intended to treat hallucinations and delusions associated with Alzheimer’s disease psychosis.
We delve into what's next for the Company in our article today!
Read on to know more:
https://www.aviseanalytics.com/acadia-pharmac...fda-adcom/
$ACAD
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company developing small molecule drugs for treating central nervous system disorders, faced a setback at the FDA's Psychopharmacologic Drugs Advisory Committee (PDAC) meeting for pimavanserin, a drug intended to treat hallucinations and delusions associated with Alzheimer’s disease psychosis.
We delve into what's next for the Company in our article today!
Read on to know more:
https://www.aviseanalytics.com/acadia-pharmac...fda-adcom/
(0)
(0)Scroll down for more posts ▼
